دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
From research to policy: still a long way to go
doi : 10.1016/S2213-8587(23)00367-4
Volume 12, Issue 1, January 2024, Page 1
New clarity for managing statin intolerance in diabetes
doi : 10.1016/S2213-8587(23)00352-2
Volume 12, Issue 1, January 2024, Pages 2-3
The role of vitamin D in paediatric bone health
doi : 10.1016/S2213-8587(23)00353-4
Volume 12, Issue 1, January 2024, Pages 4-5
Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR
doi : 10.1016/S2213-8587(23)00355-8
Volume 12, Issue 1, January 2024, Pages 5-8
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
doi : 10.1016/S2213-8587(23)00364-9
Volume 12, Issue 1, January 2024, Page 8
The Lancet Diabetes & Endocrinology Commission on type 1 diabetes: looking back to move forward
doi : 10.1016/S2213-8587(23)00323-6
Volume 12, Issue 1, January 2024, Pages 9-11
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?
South Africa to produce insulin for Africa in 2024
doi : 10.1016/S2213-8587(23)00357-1
Volume 12, Issue 1, January 2024, Page 18
Correction to Lancet Diabetes Endocrinol 2023; 11: 798–810
doi : 10.1016/S2213-8587(23)00350-9
Volume 12, Issue 1, January 2024, Page e1
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14
doi : 10.1016/S2213-8587(23)00360-1
Volume 12, Issue 1, January 2024, Page e1
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54
doi : 10.1016/S2213-8587(23)00362-5
Volume 12, Issue 1, January 2024, Page e1
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
doi : 10.1016/S2213-8587(23)00316-9
Volume 12, Issue 1, January 2024, Pages 19-28
Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial
doi : 10.1016/S2213-8587(23)00317-0
Volume 12, Issue 1, January 2024, Pages 29-38
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
doi : 10.1016/S2213-8587(23)00321-2
Volume 12, Issue 1, January 2024, Pages 39-50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
doi : 10.1016/S2213-8587(23)00322-4
Volume 12, Issue 1, January 2024, Pages 51-60
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
doi : 10.1016/S2213-8587(23)00287-5
Volume 12, Issue 1, January 2024, Pages e2-e11
Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations
doi : 10.1016/S2213-8587(23)00347-9
Volume 12, Issue 1, January 2024, Pages 61-82
